H.C. Wainwright 23rd Annual Global Investment Conference
Mon., Sept. 13, 2021
Fireside chat available on-demand beginning at 7:00 a.m. ET
Cell & Gene Therapy World Asia 2021 conference
Wed., Sept. 15, 2021
Presentation Time: 4:45 PM (SGT)
Keynote Presentation Topic: VB-111: Transformative Gene therapy with the Potential to Change the Treatment Paradigm for Solid Tumors
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Wed., Sept. 22, 2021
Fireside chat at 1:15 PM – 1:55 PM (ET).
Webcasts will be available via the Events and Presentations section of the Company’s Investor Relations page.
About VBL Therapeutics
Vascular Biogenics Ltd., operating as VBL Therapeutics (VBL), is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer and immune or inflammatory indications. VBL has developed three platform technologies: a gene-therapy based platform for targeting newly formed blood vessels with focus on cancer, an antibody-based platform targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the lecinoxoids platform, comprised of a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111; `ofra-vec`), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent in development to treat a wide range of solid tumors. VB-111 is currently being studied in a Phase 3 registration-enabling trial for platinum-resistant ovarian cancer. To learn more about VBL Therapeutics, please visit vblrx.com or follow the company on LinkedIn, Twitter, YouTube or Facebook.